Table 1.
Clinical characteristics of included patients
| Total LVV | TAK | LV-GCA | |
| n=100 | n=53 | n=47 | |
| Age (years) at diagnosis, median (IQR) | 48 (29.5–62.5) | 31 (23–38) | 63 (57–71) |
| Sex, n (%), Male | 22 (22%) | 6 (11.3%) | 16 (34.0%) |
| Female | 78 (78%) | 47 (88.7%) | 31 (66.0%) |
| Newly diagnosed (%) | 25 (25%) | 6 (11.3%) | 19 (40.4%) |
| Disease activity, n (%), Inactive | 57 (57%) | 34 (64.2%) | 23 (48.9%) |
| Active | 43 (43%) | 19 (35.8%) | 24 (51.1%) |
| ESR (mm/hour), median (IQR), missing=1 | 27 (13–64) | 22 (11–40) | 33.5 (14–81) |
| CRP (mg/dL), median (IQR), missing=2 | 0.84 (0.3–3.1) | 0.8 (0.3–2.0) | 1.68 (0.3–6.9) |
| Vascular symptoms, n (%), missing=1 | 23 (23.2%) | 14 (26.4%) | 9 (19.6%) |
| Systemic symptoms, n (%), missing=1 | 22 (22.2%) | 7 (13.2%) | 15 (32.6%) |
| Cranial symptoms, n (%), missing=1 | 7 (7.1%) | 2 (3.8%) | 5 (10.9%) |
| Visual manifestations, n (%), missing=1 | 2 (2.0%) | 1 (1.9%) | 1 (2.2%) |
| Polymyalgia rheumatica, n (%), missing=1 | 7 (7.1%) | 0 (0.0%) | 7 (15.2%) |
| Patients with at least one synchronous stenosis or dilation, n (%) | 57 (57%) | 34 (64.2%) | 23 (48.9%) |
| Patients with at least one follow-up CTA / MRA performed between 6 and 30 months from baseline PET, n (%) | 28 (28%) | 20 (37.7%) | 8 (17%) |
| Patients with at least one incident stenosis or dilation, n (%) | 4 (14%) | 4 (20%) | 0 (0%) |
Clinical characteristics of the overall LVV population and of the subgroups with TAK and LV-GCA at baseline assessment, and outcome measures.
CRP, C reactive protein; CTA, CT angiography; ESR, erythrocyte sedimentation rate; LV-GCA, large vessel-giant cell arteritis; LVV, large vessel vasculitis; MRA, MR angiography; PET, positron emission tomography; TAK, Takayasu arteritis; WBC, white blood cell.